Online citations, reference lists, and bibliographies.
← Back to Search

Preoperative Tumor Volume Is Associated With Outcome In Malignant Pleural Mesothelioma.

H. Pass, B. Temeck, K. Kranda, S. Steinberg, I. Feuerstein
Published 1998 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
OBJECTIVES Our objective was to analyze the impact of preoperative and postresection solid tumor volumes on outcomes in 47 of 48 consecutive patients undergoing resection for malignant pleural mesothelioma who were treated prospectively and randomized to photodynamic therapy or no photodynamic therapy. METHODS From July 1993 to June 1996, 48 patients with malignant pleural mesothelioma had cytoreductive debulking to 5 mm or less residual tumor by extrapleural pneumonectomy (n = 25) or pleurectomy/decortication (n = 23). Three-dimensional computed tomographic reconstructions of preresection and postresection solid tumor were prospectively performed and the disease was staged postoperatively according to the new International Mesothelioma Interest Group staging. RESULTS Median survival for all patients is 14.4 months (extrapleural pneumonectomy, 11 months; pleurectomy/decortication, 22 months; p2 = 0.07). Median survival for preoperative volume less than 100 was 22 months versus 11 months if more than 100 cc, p2 = 0.03. Median survival for postoperative volume less than 9 cc was 25 months versus 9 months if more than 9 cc, p2 = 0.0002. Thirty-two of forty-seven (68%) had positive N1 or N2 nodes. Tumor volumes associated with negative nodes were significantly smaller (median 51 cc) than those with positive nodes (median 166 cc, p2 = 0.01). Progressively higher stage was associated with higher median preoperative volume: stage I, 4 cc; stage II, 94 cc; stage III, 143 cc; stage IV, 505 cc; p2 = 0.007 for stage I versus II versus III versus IV. Patients with preoperative tumor volumes greater than 52 cc had shorter progression-free intervals (8 months) than those 51 cc or less (11 months; p2 = 0.02). CONCLUSIONS Preresection tumor volume is representative of T status in malignant pleural mesothelioma and can predict overall and progression-free survival, as well as postoperative stage. Large volumes are associated with nodal spread, and postresection residual tumor burden may predict outcome.
This paper references



This paper is referenced by
10.1097/JTO.0b013e3181dd0ef1
Assessment of Therapy Responses and Prediction of Survival in Malignant Pleural Mesothelioma Through Computer-Aided Volumetric Measurement on Computed Tomography Scans
F. Liu (2010)
10.21037/jtd.2018.01.23
Staging in the era of international databases: documented improvements with remaining challenges.
R. Cameron (2018)
10.1016/J.LUNGCAN.2004.04.012
Prognostic factors in malignant mesothelioma.
J. Burgers (2004)
10.1016/J.HOC.2005.09.002
The radiologic measurement of mesothelioma.
S. Armato (2005)
10.1097/JTO.0b013e3181c5e366
Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials
P. Paik (2010)
10.1016/j.jfma.2018.04.001
Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.
Ting-Hui Wu (2019)
10.1016/j.jtcvs.2018.09.106
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma
M. Hashimoto (2019)
10.1016/j.jtho.2016.09.123
The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation
H. Pass (2016)
10.1016/j.ejcts.2010.08.028
Staging malignant pleural mesothelioma: additional investigation may not improve accuracy.
D. West (2011)
10.1067/MTC.2002.128577
Pleural mesothelioma in 2002: going somewhere very slowly.
H. Pass (2002)
10.1016/B978-1-4160-3624-1.00001-9
1 – Imaging Tumors of the Lung and Pleura
E. Marom (2010)
10.1016/j.jtcvs.2008.02.069
The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system.
R. Flores (2008)
10.1378/CHEST.123.2.551
Surgical treatment of malignant pleural mesothelioma: a review.
S. van Ruth (2003)
10.1007/978-3-642-10862-4_3
Imaging of mesothelioma.
R. Gill (2011)
10.1097/01.LBR.0000011079.00225.DF
Treatment of Mesotheliomatous Pleural Effusion: Experimental Therapy versus Thoracoscopic Talc Poudrage? Pro: Talc Poudrage Therapy
Y. Aelony (2001)
10.1016/S1525-7304(11)70322-9
Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1245/s10434-011-1728-x
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Mbbs Christopher Cao BSc (2011)
10.2217/LMT.14.26
Systematic review on pleurectomy/ decortication in the multimodality treatment of malignant pleural mesothelioma
S. Sestini (2014)
10.1016/J.LUNGCAN.2004.11.003
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary.
D. Maziak (2005)
10.1016/S1572-1000(05)00059-1
Photodynamic therapy in the management of malignant pleural mesothelioma: A review.
K. Moghissi (2005)
10.1248/JHS.53.23
Relationship between tumorsize of malignant pleural mesothelioma and its response to chemotherapy
H. Ozden (2007)
10.1016/j.lungcan.2020.09.025
A comparison between MRI and CT in the assessment of primary tumour volume in mesothelioma.
S. Tsim (2020)
10.1016/j.lungcan.2018.11.033
Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
S. Armato (2019)
DRAMATIC TUMOUR RESPONSE TO PEMETREXED THERAPY IN MALIGN MESOTHELIOMA IN AN OLD PATIENT
O. Turan (2010)
10.1117/1.JMI.7.1.012705
Deep learning-based segmentation of malignant pleural mesothelioma tumor on computed tomography scans: application to scans demonstrating pleural effusion
E. Gudmundsson (2020)
10.1007/978-1-84882-710-3_8
Monitoring Responses to Therapy in Oncology
B. Zhao (2014)
10.1007/0-387-28274-2_28
Radiologic Assessment of Mesothelioma
S. Armato (2005)
10.1592/phco.26.5.641
Pemetrexed, a Novel Antifolate Therapeutic Alternative for Cancer Chemotherapy
Leticia R. Villela (2006)
10.1007/0-387-31056-8_38
Therapy for malignant pleural mesothelioma
H. Pass (2006)
10.1007/s00520-008-0405-5
Surgical and other invasive approaches to recurrent pleural effusion with malignant etiology
S. Neragi-Miandoab (2008)
10.1016/J.LUNGCAN.2004.04.020
Chemotherapy for malignant pleural mesothelioma: past results and recent developments.
S. Tomek (2004)
10.1200/JCO.2001.19.2.551
Comparison of diameter and perimeter methods for tumor volume calculation.
A. G. Sorensen (2001)
See more
Semantic Scholar Logo Some data provided by SemanticScholar